AbbVie Earnings Call Highlights New Growth Leaders

Abbvie ((ABBV)) has held its Q1 earnings call. Read on for the main highlights of the call.

AbbVie’s latest earnings call struck a distinctly upbeat tone, underscoring strong commercial momentum, broad-based revenue growth and a confidence-fueled guidance raise. Management acknowledged expected pressure in legacy and select oncology and aesthetics franchises, but emphasized that outsized gains in immunology and neuroscience plus visible pipeline progress more than offset the headwinds.

Quarterly Beat Underscores Earnings Power

AbbVie opened the quarter with a clean beat on both the top and bottom lines, reinforcing its post‑HUMIRA transition story. Adjusted EPS came in at $2.65, or $0.07 above the guidance midpoint, while total net revenues reached $15.0 billion, about $300 million ahead of expectations and translating into robust 12.4% year‑over‑year sales growth.

Guidance Raised on Strong Revenue Trajectory

On the back of this upside, the company nudged its full‑year adjusted EPS guidance higher by $0.12 to a range of $14.08 to $14.28. AbbVie also increased its full‑year revenue outlook to roughly $67.3 billion, up $300 million versus prior plans, signaling management’s conviction that current growth trends are not just a one‑quarter phenomenon.

Immunology Engine Driven by Skyrizi and Rinvoq

The immunology franchise again did the heavy lifting, delivering $7.3 billion in revenue, up $1.0 billion from a year earlier as new therapies scale rapidly. Skyrizi sales climbed 29.2% operationally to $4.5 billion and Rinvoq advanced 20.2% to $2.1 billion, with management highlighting steady share gains in psoriasis, psoriatic arthritis and inflammatory bowel disease.

IBD Momentum Puts Skyrizi in the Spotlight

In inflammatory bowel disease specifically, Skyrizi is on track to post more than 30% global sales growth this year, solidifying its role as a next‑generation anchor asset as HUMIRA erodes. The company framed IBD as a long‑duration growth vector, driven by both expanding indications and deeper penetration among moderate‑to‑severe patients.

Neuroscience Portfolio Delivers Double‑Digit Growth

Neuroscience remained another standout, with revenues approaching $2.9 billion, up 24.3% on an operational basis, again showing the breadth of AbbVie’s growth base. Flagship antipsychotic Vraylar generated $905 million, growing 18.4%, while newer launch VYALEV posted $201 million and nearly 10% sequential growth, supporting management’s bullish read‑through for the category.

Preparing for Parkinson’s Launch Upside

Looking ahead, AbbVie is gearing up for a potential U.S. approval and launch of tavapadon in Parkinson’s disease later this year. Management framed tavapadon as an important next step in its neuroscience strategy, one that could expand the company’s presence in movement disorders and add another durable growth driver if the launch executes well.

Migraine and Botox Franchise Shows Category Strength

Beyond core immunology and neuroscience, AbbVie pointed to selected brands showing strong performance and category leadership. The migraine portfolio, including Botox Therapeutic, is delivering robust double‑digit growth, while Botox Cosmetic generated $668 million in revenue, rising 17% and underscoring the enduring demand for neurotoxins even amid macro uncertainty.

Skyrizi Data Deepens Competitive Moat

The company also highlighted clinical data that should help defend Skyrizi’s leading position in immunology for years to come. Long‑term radiographic results in psoriatic arthritis showed nearly 90% of patients experienced no radiographic progression at five years, and new label additions for hard‑to‑treat psoriasis areas provide further differentiation in a crowded market.

Regulatory Momentum for Key Immunology Assets

Pipeline progress featured prominently, with management stressing several recent regulatory moves designed to widen the reach of existing blockbusters. AbbVie has submitted Rinvoq in the U.S. for alopecia areata and filed for Skyrizi subcutaneous induction in Crohn’s disease, with an approval decision expected later this year, both of which could expand the commercial opportunity.

Combination Data Signals Next Wave in Crohn’s

Early‑stage combination data in Crohn’s disease for Skyrizi plus ABBV‑382 were described as potentially transformational, suggesting higher efficacy could be possible through combination approaches. While still early, these outcomes support AbbVie’s strategy of layering novel mechanisms onto its existing immunology backbone to sustain an innovation edge.

Obesity Candidate ABBV‑295 Shows Early Promise

Investors also received an early look at AbbVie’s obesity ambitions through the long‑acting amylin analog ABBV‑295, which posted encouraging Phase I results. In a multiple‑ascending‑dose study, the drug delivered nearly 10% weight loss over 12 weeks in a predominantly male, nonobese cohort with favorable tolerability, hinting at competitive potential in a large and rapidly evolving market.

Long Half‑Life Suggests Flexible Obesity Dosing

ABBV‑295’s roughly 270‑hour half‑life could translate into convenient every‑other‑week or even monthly dosing in future trials, a potential advantage as the obesity field increasingly competes on both efficacy and patient experience. Management cautioned that it remains early, but framed these data as an important proof‑of‑concept for AbbVie’s metabolic pipeline.

Oncology Portfolio Re‑Tools via Business Development

In oncology, AbbVie leaned on external business development and portfolio optimization to refresh its growth prospects amid pressure on legacy assets. The company expanded its pipeline through an agreement with Remagen for a PD‑1/VEGF bispecific, a mechanism designed to intensify anti‑tumor activity and potentially open doors in difficult‑to‑treat solid tumors.

Temab‑A Strategy Shifts to Combinations

AbbVie also detailed a strategy shift for Temab‑A, pivoting toward combination use with bevacizumab in all‑comers colorectal cancer after encouraging early signals. The combo has shown an objective response rate of about 30% and a disease control rate near 97%, and the company is planning multiple ASCO readouts and discussions around accelerating development timelines.

Major U.S. Manufacturing Investments Announced

Reinforcing its long‑term outlook, AbbVie announced sizable capital investments as part of a broader $100 billion U.S. R&D and capital commitment. The company will spend $1.4 billion on a new pharmaceutical campus in North Carolina and $380 million on two plants in North Chicago, moves aimed at ensuring ample capacity for its expanding product lineup.

Capacity Build‑Out Supports Growth Pipeline

Management framed these projects as essential to supporting projected volume growth across immunology, neuroscience and emerging areas such as obesity while also strengthening supply chain resilience. For investors, these investments underline AbbVie’s expectation that current growth drivers, plus the pipeline, will require significantly more manufacturing scale over the coming decade.

Margins Remain a Core Strength

Profitability stayed a key focus, with AbbVie delivering an adjusted gross margin of 83.6% and an adjusted operating margin of 40.8% in the quarter despite higher R&D investment. For the full year, the company is targeting an adjusted gross margin above 84% and an adjusted operating margin ratio around 47.5%, highlighting the earnings leverage embedded in the model.

IPR&D Provides a Near‑Term Drag on EPS

The company did note that acquired in‑process R&D weighed significantly on Q1 profitability, representing a $0.41 unfavorable impact to EPS and around a 5% drag on the adjusted operating margin ratio. Guidance explicitly excludes any future acquired IPR&D beyond Q1, which adds a layer of uncertainty around how aggressive AbbVie will be on external innovation deals later in the year.

Balance Sheet and Capital Returns Offer Flexibility

On the capital allocation front, AbbVie highlighted improved financial flexibility alongside its growth investments, as adjusted net interest expense guidance was reduced to about $2.7 billion, an improvement of roughly $100 million. Management reiterated its commitment to record levels of internal investment, ongoing business development and returning cash to shareholders via a growing dividend.

HUMIRA Erosion Continues as Planned

Against this backdrop of growth, the company is still managing through the predictable decline of HUMIRA, which is facing heavy global biosimilar competition. HUMIRA sales fell to $688 million in the quarter, down 40.3% on an operational basis, but management emphasized that newer therapies are now more than offsetting the drag and reshaping the portfolio mix.

Oncology Revenues Reflect Competitive and Policy Pressure

Not all franchises moved in the right direction, as total oncology revenue dipped 3% operationally to $1.6 billion amid mounting competition and policy headwinds. IMBRUVICA bore the brunt, with sales down 24.7% due to pricing impacts and share losses, though Venclexta partially offset the decline with 9.7% growth to $770 million.

Aesthetics Growth Uneven as Fillers Lag

The aesthetics segment posted nearly $1.2 billion in revenue, representing 5.1% operational growth but masking divergent trends under the surface. While Botox Cosmetic continued to expand at a healthy clip, Juvederm dermal filler sales slipped 2.9% to $232 million, and management flagged continued macro‑driven weakness in filler markets versus historical downturns.

Regulatory Setback Adds to Aesthetics Uncertainty

Adding to the mixed picture, an unnamed aesthetics application received a Complete Response Letter from regulators related to manufacturing issues, though no safety or efficacy concerns were cited. Management acknowledged that, combined with softer filler dynamics, the overall aesthetics category appears more pressured this cycle and may see a slower near‑term recovery than in past recessions.

Targeted Pipeline Pruning After Mixed Clinical Results

The call also addressed clinical setbacks that prompted AbbVie to trim parts of its pipeline, a reminder that not all bets will pay off. Phase II data for ABBV‑932 in bipolar depression failed to meet the primary endpoint overall, and while a signal emerged in the bipolar I subgroup, the company is reassessing the path forward, while discontinuing Skyrizi plus lutikizumab combinations due to insufficient differentiation.

Pricing and Inventory Dynamics Remain Manageable

From a commercial standpoint, AbbVie is bracing for modest pricing pressure in key markets but views it as manageable relative to volume growth. Management projected low single‑digit net price erosion across immunology for the full year, noting that Skyrizi pricing was flat in Q1 and that the quarter also absorbed a modest inventory destocking impact.

Data and Regulatory Timing Add Execution Risk

Finally, AbbVie acknowledged operational and modeling uncertainty around several early‑stage programs and upcoming regulatory interactions, particularly in oncology. The exact timing of pivotal study designs, data readouts and filings remains fluid, which could lead to uneven news flow and requires investors to factor in execution risk alongside the otherwise strong growth narrative.

Updated Outlook and Forward Guidance

Looking ahead, AbbVie’s raised guidance calls for full‑year 2026 adjusted EPS of $14.08 to $14.28 and about $67.3 billion in net revenues, underpinned by higher assumptions for several flagship products. Management now expects Skyrizi to generate $21.6 billion, Rinvoq $10.2 billion and total neuroscience $12.6 billion, supported by an adjusted gross margin above 84%, a roughly 47.5% operating margin, lower net interest expense of $2.7 billion and Q2 revenues around $16.7 billion with a modest FX tailwind.

AbbVie’s earnings call painted the picture of a company successfully transitioning beyond its legacy blockbuster while investing heavily in its next wave of growth. For investors, accelerating contributions from Skyrizi, Rinvoq and neuroscience, disciplined capital deployment and clear margin ambition offset concerns around HUMIRA erosion, oncology pressure and aesthetics volatility, leaving the stock levered to a multi‑year growth and innovation cycle.